Trial Profile
A Phase 2 Study of PXD101 in Platinum Resistant Epithelial Ovarian Tumors and Micropapillary/Borderline (LMP) Ovarian Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Aug 2018
Price :
$35
*
At a glance
- Drugs Belinostat (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 13 Dec 2016 Status changed from active, no longer recruiting to completed.
- 11 Apr 2013 Planned End Date changed from 1 Jan 2008 to 1 Aug 2009 as reported by ClinicalTrials.gov.
- 25 Feb 2009 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.